View of Comparative Efficacy of Anastrozole, Letrozole, and Fulvestrant as Endocrine Partners Combined with CDK4/6 Inhibitors in Patients with HR+/HER2– Metastatic Breast Cancer: A Real-World Evidence from the Stavropol Regional Clinical Oncology Center | Voprosy onkologii

← Comparative Efficacy of Anastrozole, Letrozole, and Fulvestrant as Endocrine Partners Combined with CDK4/6 Inhibitors in Patients with HR+/HER2– Metastatic Breast Cancer: A Real-World Evidence from the Stavropol Regional Clinical Oncology Center